Defined Bioscience today announced that its pluripotent stem cell culture reagents, including HiDef® B8, are incorporated into a newly launched induced pluripotent stem cell (iPSC) transfection platform, the PluriForm™-GFP-3D Transfection Kit, developed by Pluristyx in collaboration with Solesis.
The Pluristyx platform enables highly efficient mRNA delivery directly in suspension-adapted iPSC, achieving uniform, nearly 100% transfection efficiency with a single mRNA delivery. Defined Bioscience’s HiDef-B8 fully defined, animal-free media is used within the platform to support robust and efficient pluripotent cell transgene expression and cell expansion to complement the transfection chemistry and process developed by Pluristyx and Solesis.
“As iPSC workflows move toward suspension culture and higher levels of automation, having a reliable and well-characterized culture medium becomes increasingly important,” said Steven Rees, PhD, Co-Founder and CEO of Defined Bioscience. “We’re pleased to have HiDef-B8 integrated into Pluristyx’s new transfection platform as part of a broader, end-to-end solution for iPSC engineering.”
The platform combines Defined Bioscience’s media, Solesis’ optimized transfection polymer chemistry, and Pluristyx’s proprietary mRNA technology and pluripotent stem cell lines and expertise in scalable manufacturing and process development, addressing key challenges in iPSC modification, including efficiency, consistency, and process integration.
“Integrating Defined Bioscience’s fully defined, animal-free media component into our PluriForm transfection platform has allowed us to convert a complex, weeks-long optimization process into a simple, off-the-shelf workflow. The team and technology from Defined Bioscience have enabled us to deliver a much needed and unique solution to the market” said Dr. Benjamin Fryer, Co-Founder and CEO of Pluristyx.
The collaboration highlights a growing trend in the field toward modular, integrated technologies that allow researchers and developers to rapidly and reproducibly assemble robust pluripotent stem cell workflows for research, development, diagnostics, and therapeutics from best-in-class components.
Meet Us at Advanced Therapies Week
Leadership from Defined Bioscience, Pluristyx, and Solesis will be attending Advanced Therapies Week in San Diego. The teams are available to meet with attendees to discuss the newly launched iPSC transfection platform and how integrated culture, transfection, and manufacturing solutions can support scalable pluripotent stem cell workflows. To schedule a meeting, please contact Dr. Steven Rees (steve@definedbioscience.com), Dr. Priya Baraniak (priya@pluristyx.com), or Mr. Ian Burdick (ian.burdick@solesis.com).
About Defined Bioscience
Defined Bioscience develops rationally designed, animal-free media and supplements that support reproducible and scalable human pluripotent stem cell culture. Its HiDef® product line enables high-density expansion, suspension culture, and differentiation of iPSCs across research, organoid, and translational workflows. Defined Bioscience’s formulations are built on fully defined components to improve consistency, reduce variability, and facilitate downstream process development. For more information, visit www.definedbioscience.com.
About Pluristyx, Inc.
Pluristyx is dedicated to enabling the development of next-generation cell-based tools and therapies through scalable, high-performance pluripotent stem cell platforms. Its product portfolio, including PluriKit™, PluriForm™ aggregates, and PluriBank™ stem cells, supports efficient iPSC expansion, engineering, and differentiation for research and translational applications. Pluristyx’s iPSC lines are available off-the-shelf along with technical and regulatory support services to accelerate the development of diagnostics, screening platforms, and therapeutic programs. For more information, visit www.pluristyx.com.
About Solesis, LLC
Solesis is a market leader in custom design, development, and manufacturing of textile- and polymer-based healthcare solutions. Through its operating subsidiaries, Charter Medical, Polyzen, and Secant Group, Solesis develops critical components and technologies for the medical device and biopharmaceutical industries, including developing biomaterial platforms for transfection and drug delivery applications. Headquartered in Telford, Pennsylvania, Solesis operates multiple manufacturing facilities across the United States and Costa Rica. For more information, visit www.solesis.com.
